Results 21 to 30 of about 22,142 (188)

Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia Case report and literature review [PDF]

, 2019
Introduction: Ibrutinib is an oral inhibitor of Bruton's tyrosine kinase that is used for a variety of B cell hematological malignancies. Skin and subcutaneous tissue manifestations have been reported and were witnessed in up to 32% of the patients on ...
Albattah, A, Nemir, A, Ghasoub, R, I Alhijji (18112825), R Ghasoub (18112810), Alhijji, I, Taha, R, A Nemir (18112822), Elazzazy, S, R Taha (18112828), Alokka, R, R Alokka (18112819), S Elazzazy (18112816), A Albattah (18112813)   +13 more
core   +1 more source

RETRACTED ARTICLE: Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway

Cell Death and Disease, 2023
Ibrutinib is a drug that inhibits the protein Burton’s tyrosine kinase and thereby the nuclear translocation of Nrf2, which played a key role in mediating the activation of antioxidants during stress conditions and ferroptosis resistance.
Jin-Feng Zhu, Yi Liu, Wen-Ting Li, Ming-Hui Li, Chao-Hui Zhen, Pei-Wei Sun, Ji-Xin Chen, Wen-Hao Wu, Wei Zeng   +8 more
doaj   +1 more source

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells

eJHaem, 2021
ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi, Mohammad‐Ali Okhovat, Layung Sekar Sih Wikanthi, Ann Svensson, Marzia Palma, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat‐Farsangi   +9 more
doaj   +1 more source

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Journal for ImmunoTherapy of Cancer, 2023
Background In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy.
Li Zhang, Matthew Crocker, Lawrence Fong, Lisa M Coussens, Charles D Lopez, Shamilene Sivagnanam, Meenal Sinha, Brandon Chen, Jaqueline Marquez, Alexander Cheung, Whitney Tamaki, Jacob Stultz, Kendra Todd, Courtney Betts, Madeline J Griffith, Isabelle Solman, Eric Liu, Denise Pener, Anne Fahlman, Erin Taber, Kimberly Lerner, Brindha Rajagopalan, Clarisha Ware, Mark Bridge, Johnson Vo, Hannah Dragomanovich, Julie Sudduth-Klinger, Gina Vaccaro, Margaret Tempero   +28 more
doaj   +1 more source

Ibrutinib: From Molecule to Medicine

, 2014
İbrutinib: Molekülden İlacaBruton tirozin kinaz (BTK) inhibitörü Ibrutinib (PCI-32765), BTK üzerine irreversibl kovalan bağlanarak BCR aktivitesini yönlendiren yeni bir hedeflenmiş tedavi ajanıdır.
Ayyıldız, Orhan, Göker, Hakan, Kaynar, Leyla G, Haznedaroğlu, İbrahim C., Saydam, Güray, İlhan, Osman, Demirkan, Fatih   +6 more
core   +3 more sources

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13) [PDF]

, 2023
BACKGROUND The Bruton's tyrosine kinase inhibitor ibrutinib and the proteasome inhibitor bortezomib have single-agent activity, non-overlapping toxicities, and regulatory approval in mantle cell lymphoma (MCL).
Urban Novak, Ferrero, Simone, Nicolas Mach, Dreyling, Martin, Mey, Ulrich, Renner, Christoph, Thilo Zander, Driessen, Christoph, Christoph Renner, Voegeli, Michèle, Zucca, Emanuele, Anne Cairoli, Carola Boccomini, Menter, Thomas, Dirnhofer, Stefan, Georg Hess, Sebastian Böttcher, Vanesa-Sindi Ivanova, Ulrich Mey, Boccomini, Carola, Ivanova, Vanesa-Sindi, Sämi Schär, Enrico Derenzini, Eckhardt, Katrin, Simone Ferrero, Zander, Thilo, Hess, Georg, Derenzini, Enrico, Martin Dreyling, Mach, Nicolas, Martin Fehr, Schär, Sämi, Bernhard Scheibe, Sandra Gadient, Christoph Driessen, Böttcher, Sebastian, Scheibe, Bernhard, Katrin Eckhardt, Schmidt, Christian, Fehr, Martin, Cairoli, Anne, Gadient, Sandra, Christian Schmidt, Emanuele Zucca, Michèle Voegeli, Stefan Dirnhofer, Thomas Menter, Novak, Urban   +47 more
core   +2 more sources

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma

Blood Advances, 2018
: The BTK inhibitor ibrutinib has demonstrated a remarkable therapeutic effect in mantle cell lymphoma (MCL). However, approximately one-third of patients do not respond to the drug initially.
Jimmy Lee, Liang Leo Zhang, Wenjun Wu, Hui Guo, Yan Li, Madina Sukhanova, Girish Venkataraman, Hui Zhang, Mir Alikhan, Pin Lu, Ailin Guo, Natalie Galanina, Jorge Andrade, Michael L. Wang, Y. Lynn Wang   +14 more
doaj   +1 more source

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. [PDF]

, 2014
BACKGROUND: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome.
Thornton, P, Schuh, A, Moreno, C, Brown, Jr, Robak, T, Reddy, Nm, Byrd, Jc, Bloor, A, Jaeger, U, de Vos, S, SEMENZATO, GIANPIETRO CARLO, Kipps, Tj, James, Df, Delgado, J, Devereux, S, Montillo, M, Barr, Pm, Clow, F, Caligaris-Cappio, F, Pocock, C, Tam, Cs, Cymbalista, F, Schuster, Sj, Gill, D, Coutre, S, O'Brien, S, Fardis, M, Caligaris Cappio, F, Mulligan, Sp, Jones, Jj, Dearden, C, Kay, Ne, Chu, Ad, Mcgreivy, J, Furman, Rr, Hillmen, P, Barrientos, Jc   +36 more
core   +3 more sources

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemi: Phase 3 analysis [PDF]

, 2019
Only Vanderbilt University affiliated authors are listed on VUIR. For a full list of authors, access the version of record at https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.25436The efficacy of ibrutinib has been demonstrated in patients with ...
Reddy, Nishitha M.
core   +2 more sources

A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy

Medical Mycology Case Reports, 2020
Ibrutinib has revolutionized the treatment of chronic lymphoid malignancies. Despite its success, ibrutinib has been linked with several reports of invasive fungal infections.
Emily M. Eichenberger, Jennifer Saullo, Danielle Brander, Shih-Hsiu Wang, John R. Perfect, Julia A. Messina   +5 more
doaj   +1 more source